Skip to main content

onc206

Generic: DRD2 Antagonist/ClpP Agonist ONC206·Code: ONC206

onc206: 3 clinical trials tracked.

onc206 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about onc206, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (3)

A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma

NCT07282587Registry updated 2026-10-02·Phase 2·JAZZ
Recruiting

Primary endpoint: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

InterventionalRandomizedopen90 targetStarted 2026-01Completion 2028-129 sites · United StatesJazz Pharmaceuticals

Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

NCT04732065Registry updated 2026-06-11·Phase 1
Recruiting

Primary endpoint: Proportion of participants with dose-limiting toxicities (DLT)

Interventionalopen208 targetStarted 2021-08Completion 2027-077 sites · Netherlands, Switzerland, United StatesSabine Mueller, MD, PhD

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

NCT04541082Registry updated 2025-12-18·Phase 1·JAZZ
Recruiting

Primary endpoint: Maximum Tolerated Dose (MTD) of single-agent, oral ONC206

Interventionalopen102 targetStarted 2020-10Completion 2026-121 site · United StatesJazz Pharmaceuticals